Mathematical modelling studies of C. trachomatis transmission predict that interventions to screen and treat chlamydia infection will reduce prevalence to a greater degree than that observed in empirical population-based studies. We investigated two factors that might explain this discrepancy: partial immunity after natural infection clearance and differential screening coverage according to infection risk. We used four variants of a compartmental model for heterosexual C. trachomatis transmission, parameterized using data from England about sexual behaviour and C. trachomatis testing, diagnosis and prevalence, and Markov Chain Monte Carlo methods for statistical inference. A model in which partial immunity follows natural infection clearance and the proportion of tests done in chlamydia-infected people decreases over time fitted the data best. The model predicts that partial immunity reduced susceptibility to reinfection by 72% (95% Bayesian credible interval 57-86%). The estimated screening rate was 4.6 (2.6-6.5) times higher for infected than for uninfected women in 2000; this decreased to 2.1 (1.4-2.9) in 2011. Other factors not included in the model could have further reduced the expected impact of screening. Future mathematical modelling studies investigating the effects of screening interventions on C. trachomatis transmission should incorporate host immunity and changes over time in the targeting of screening. 3
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INTRODUCTION
There is ongoing debate about the evidence to support screening for Chlamydia trachomatis (chlamydia) infection to reduce prevalence. [1] [2] [3] C. trachomatis is the most commonly reported bacterial sexually transmitted infection (STI) in high-income countries; in 2016, about 128,000 cases of C. trachomatis were diagnosed among young people aged 15-24 years in England 4 and over 1 million in the United States of America 5 . C. trachomatis can cause pelvic inflammatory disease (PID) in women, which can lead to ectopic pregnancy and tubal factor infertility. 6 However, C. trachomatis infection is often asymptomatic, so screening has been promoted to detect and treat asymptomatic infection to prevent reproductive tract morbidity and reduce transmission. In England, screening for chlamydia increased considerably with the National Chlamydia Screening Programme (NCSP) in 2003. Through the NCSP, free opportunistic screening is offered to sexually active women and men under 25 years of age, with nationwide roll-out achieved in 2008. Testing coverage in young women increased from 4% in 2000 to 35% in 2012. 7 However, chlamydia prevalence, estimated in two cross-sectional population-based British National Surveys of Sexual Attitudes and Lifestyles (Natsal) was similar in adults aged 18 to 24 years; in 1999-2001 (Natsal-2), women 3.1% (95% confidence interval, CI 1.8-5.2) and men 2.9% (1.3-6.3) and in 2010-2012 (Natsal-3). Women 3.2% (2.2-4.6) and men 2.6% (1.7-4.0). 8, 9 Transmission dynamic modelling studies predict that screening at levels achieved by the NCSP in England should reduce C. trachomatis prevalence. 10 These modelling studies describe sexual networks and the dynamics of infection transmission using different structures and levels of complexity. [11] [12] [13] [14] In a simpler model, without detailed sexual behaviour, Lewis and White inferred changes in C. trachomatis prevalence and incidence using time-series data about chlamydia testing and diagnoses in England between 2000-2015. 7, 15 Their model output proposed that prevalence had declined as chlamydia testing increased and increased as testing levels fell. An assumption in these models, irrespective of structure, is that amongst people without symptoms suggestive of infection, testing for chlamydia is not influenced by the underlying risk of infection in the screened population. In reality, the NCSP in England, and other chlamydia screening interventions, primarily test people at an increased risk of chlamydia. 16 Further, with increasing chlamydia test coverage and falling test positivity 7 , if prevalence stayed at similar levels then the proportion of tests done in those at lower risk of infection must have increased.
Immunity also affects the model-predicted impact of screening if treatment inhibits the development of immunity otherwise experienced after natural clearance of infection. 17, 18 In a model accounting for immunity, individuals that clear infection naturally are temporarily or partially protected from the force of infection which results in a less rapid turnover of C. trachomatis within the modelled population. This reduces the predicted impact of screening.
Immunity is often not included as part of the natural history in C. trachomatis transmission models 10 and, in practice, not much is known about the strength and duration of immunity.
Clinical and animal studies suggest that immunity is probably partial instead of fully protective. 19, 20 In one modelling study, Johnson and colleagues estimated a period of immunity of 6-17 years by fitting their model to chlamydia notification data, but they assumed that immunity was fully protective. 18 In this paper, we use data about sexual behaviour and the prevalence of C. trachomatis in the general population of Great Britain from Natsal-2 and Natsal-3 and time-series data about chlamydia testing and diagnoses in England and across the same time period. Using a C. trachomatis transmission model, we investigated two hypotheses about factors that might attenuate the effects of a chlamydia screening intervention: the existence of long-lasting partial immunity; and differential chlamydia test coverage according to the risk of being infected.
METHODS

Data
Natsal is conducted by face-to-face and computer-assisted questionnaire amongst a stratified random sample of the resident population of Great Britain at ten year intervals since 1990. 21 second and third most recent heterosexual partner. We aggregated these data for both surveys because there were no significant differences for these variables between the datasets. 22 We used estimates for the numbers of chlamydia tests and diagnoses from 2000 to 2011 in England from Chandra and colleagues. 7 In this study, available data from several monitoring and surveillance systems in England, including NCSP, were collated to construct plausible minimum and maximum estimates for the numbers of tests and diagnoses each year for men and women in five-year age groups: 15-19, 20-24, 25-34 and 35-44 year olds. Chlamydia testing data did not distinguish between tests provided to people with symptoms suggestive of infection with C. trachomatis and screening tests amongst people without symptoms.
Chlamydia transmission model
We developed a mathematical model to describe heterosexual C. trachomatis transmission in England from 2000 to 2011. The model uses differential equations and is described in detail in the Supplementary Information, part I; a brief summary is provided here. Model compartments and transmission rates are shown in Fig. 1 and Table 1 . behaviour and mixing between activity classes is modelled using methods proposed in a previous publication, where we accounted for differences in sexual behaviour reported by men and women. 24 People can switch between activity classes at a rate that is proportional
, , ( ) Table 1 .
to the size of these classes. 25 There is a time-dependent force of infection , , that involves the per partnership transmission probability ( ) and the heterosexual mixing patterns between ages and sexual activity classes. A fraction of all new infections is symptomatic, the remainder being asymptomatic. People in the recovered compartment are partially immune with a reduced susceptibility to reinfection.
We assumed that all symptomatically infected people receive a chlamydia test at rate χ and are subsequently treated. After treatment, symptomatically infected people become susceptible again at rate , where 1 − is the probability of treatment failure, 1 − the probability of being reinfected by a partner immediately after successful treatment and 1/ the average duration until treatment. Asymptomatically infected people can clear their infection naturally at rate , or are screened at a sex-and age-dependent rate , ( ) that depends on time t. The chlamydia screening rate amongst asymptomatic individuals differs according to the risk of being infected, which we refer to as differential screening coverage.
In the model, we define differential screening coverage as the ratio of the screening rates in asymptomatic individuals who are infected with C. trachomatis and asymptomatic individuals who are uninfected. Arguably, this ratio decreases until 2011, as more screening is offered and becomes less targeted. We model differential screening coverage by a timedependent parameter , ( ) that decreases exponentially as a function of the total yearly number of screening tests , ( ):
, � , � starts at 1 and converges to one as the number of tests , becomes large, reflecting the situation in which screening is distributed homogeneously among all people.
We then calculated the screening rate in asymptomatically infected people, , ( ), from , ( ) and , ( ) by dividing the total number of screening tests in a given year by the total number of people eligible to receive screening, accounting for the differential screening coverage between asymptomatically infected and uninfected people: ( ) 
.
(2) Factor by which susceptibility to subsequent infection is reduced through partial immunity Beta(1,1)
Parameter inference
We inferred the values of certain parameters using Markov Chain Monte Carlo (MCMC) sampling ( Table 1) . 26 We ran five separate MCMC chains for 10,000 MCMC steps. We assumed a binomial likelihood for the prevalence data and a negative binomial (NB) likelihood for the diagnoses data ( Supplementary Information, part II) . We checked convergence of the MCMC chains by computing the Gelman-Rubin convergence diagnostic. 27 We used fixed values for the sexual behaviour parameters and some of the other parameters ( , and ) ( Table 1) . To explore the sensitivity of the model outcomes to parameters , and , we varied their values by 10% and ran the same MCMC algorithm again.
Comparison of model variants
We used the chlamydia transmission model to investigate whether long-lasting partial immunity and differential screening coverage can explain discrepancies between modelpredicted effects of screening and observed data in England. We considered four different model variants (Table 2 ). In models 1 and 2 we assumed no partial immunity (by fixing to zero), whereas models 3 and 4 can account for immunity (0 < ≤ 1, estimated using MCMC). In models 1 and 3, we assumed a differential screening coverage that does not change as screening increases in time, i.e. ( 1 estimated using MCMC and fixing 2 to zero).
In models 2 and 4 we allowed for a differential screening coverage that changes as screening increases ( 1 , e and 2 both estimated using MCMC). We compared the goodness of fit of the different model variants using the deviance information criterion (DIC). 28, 29 Model code (available on request) was implemented using R version 3.4.0. 
RESULTS
The posterior probability distributions for the model-estimated parameters were different for each model variant and resulted in a different goodness of fit (DIC) to the empirical data on C. trachomatis prevalence and diagnoses ( where the composition of the screened population was assumed fixed in time or without partial immunity (Table 2) Partial immunity decreased susceptibility to reinfection after natural clearance of a first infection by 72% (95% Bayesian credible interval (CrI) 57%-86%) in model 4 ( Table 2 ). The estimate of partial immunity in the second-best fitting model 3 (fixed per capita ratio of tests in infected compared to susceptible people) was similar (70%, 95% CrI 57%-84%). about the prevalence estimates from empirical data is large due to small sample sizes. 8, 9 The model predicted a drop in prevalence for women between 15-24 years of 51% (95% CrI 47%-54%) and for men between 15-24 years of 56% (95% CrI 51%-60%), also see Fig. 5 . The mean model-predicted prevalence falls within the confidence intervals of the prevalence data for all age groups and both periods, with the exception of women aged 18-19 years in 2011.
However, some inconsistencies remain between the observed and model-predicted chlamydia prevalence. In particular, for women the mean model-predicted prevalence is higher than the mean prevalence from data for 2000 and lower for 2011 for almost all age groups.
Figure 3: Model fit to age-specific per capita number of diagnoses for men and women between 2000 and 2011. Vertical bars: Minimum and maximum estimates for number of diagnoses from Chandra and colleagues. 7 Coloured lines and shaded areas: Full model (model 4) including changes in the proportion of tests done in infected individuals and partial immunity (posterior mean and 95% Bayesian credible intervals).
Empirical data show that the per capita number of diagnoses of C. trachomatis infections has increased between 2000 and 2011 ( Fig. 3) . Although model 4 could roughly reproduce this trend, some differences remain between the model fit and the data. In general, the model shows a less steep increase in the number of diagnoses from 2000 to 2011 for men and women between 20-24 years than was estimated by Chandra and colleagues. 7 For men aged 15-19 years, the model-predicted number of diagnoses increased more steeply than observed from data.
In model 4, the expected screening rate was 4.6 (95% CrI 2.6-6.5) times higher for infected than for uninfected women in 2000; this decreased to 2.1 (95% CrI 1.4-2.9) in 2011. For men, this ratio decreased from 5.5 (95% CrI 2.7-7.9) in 2000 to 3.2 (95% CrI 2.0-4.4) in 2011 ( Fig.   4 ). The Bayesian credible intervals around these estimates are large. For men and women aged 25-44 years, we found no decrease in the ratio. The decrease in differential screening coverage in the model is the consequence of increased testing volume and not of decreased chlamydia prevalence, but it does affect prevalence. To show this, we investigated what would have happened to the predicted chlamydia prevalence if the estimated differential screening coverage as estimated for 2000 is maintained, while increasing the total number of screening tests as in the data. We used the estimated posterior distribution for 1 from model 4, while fixing 2 to zero. In this hypothetical scenario, the predicted decrease of chlamydia prevalence was significantly higher than the decrease predicted by model 4 (Fig.   5 ). A strength of this study is the availability of time-series data about chlamydia testing and diagnosis data, 7 and repeated cross-sectional surveys of C. trachomatis prevalence and sexual behavioural data from the same population over the same time period. 22, 23 The testing data avoided the need, in other modelling studies, for strong assumptions about (unobserved) levels of screening coverage. 11, 13, 30 Second, because of the importance of age as a risk factor for chlamydia, we included detailed age structure and age-dependent sexual behaviour in our model, which allowed us to estimate chlamydia prevalence in different age groups and fitted these to data about age-specific prevalence and diagnoses. 24 We made optimal use of age-specific data to estimate the values about the unknown model parameters, including those quantifying immunity and the distribution of screening tests.
Third, by synthesizing the data in a Bayesian framework we could quantify the distinct effects of partial immunity and dynamic changes in the distribution of screening tests, whilst accounting for uncertainty about the model parameters.
Our study has also limitations. First, the testing and diagnosis data, rather than the chlamydia prevalence data mainly drove the Bayesian inference in our model. Prevalence has changed over time. 31 Finally, we assumed only one level of partial immunity, which is a likely over-simplification, given the possibility of heterogeneity in immune response at the level of the individual or strain-specific immunity, and potential effects of repeat infection. It is unclear how these assumptions and levels of heterogeneity would affect our results.
The results of our study suggest that mathematical models that neglect changes over time in the distribution of screening tests among modelled subpopulations or do not include protective immunity after natural clearance of C. trachomatis [10] [11] [12] [13] [14] over-estimate the effects of screening interventions on prevalence. However, our model did not fully reconcile the model predictions with the data either, with a larger model-predicted decrease of C.
trachomatis prevalence between 2000-2011 than expected from data. 9 According to our model, screening and treating C. trachomatis-infected people resulted in a reduction in prevalence even when accounting for immunity. This finding does not support the results of a modelling study that suggested that widespread testing and treatment diminish population level immunity and can result in an increase in incidence and prevalence. 32 Other factors have been proposed as reasons for the similarity of estimated C. trachomatis prevalence in the Natsal-2 and Natsal-3 surveys. First, increases in sexual risk-taking behaviour could have resulted in increased transmission of C. trachomatis, countering the effects of screening.
However, amongst the sexual behaviours measured in Natsal-2 and Natsal-3, the only difference among heterosexual adults was a slight decrease in the proportion of men with multiple partners with whom no condoms was used. 22 We do not believe that this change would be sufficient to abolish the model-predicted reduction in prevalence and we did not investigate this possibility because our model did not explicitly include condom use. Second, a temporary reduction in C. trachomatis prevalence could have occurred during the period between the Natsal surveys. In the modelling study by Lewis and White, which also used the data on chlamydia testing and diagnoses reported by Chandra and colleagues, modelinferred prevalence decreased until 2008 and then increased back to baseline. 15 That model did not take into account differential screening coverage over time and inferred large increases in incidence to balance the increase in screening rates. 33 In theory, a reduction in the rate of successful partner notification could also limit the impact of a chlamydia screening intervention. However, in a study that compared a pair model including partner notification with a simpler model without partnerships, 34 changes in partner notification rates resulted in very modest changes in incidence. Third, it has been suggested that C.
trachomatis transmission is maintained by infection in the female rectum that is not adequately treated. 35, 36 We deemed an analysis of the role of anorectal infections beyond the scope of this study because of the uncertainty about autoinoculation probabilities.
Our findings have implications for future research and practice. First, discrepancies remain between the observed estimates of C. trachomatis prevalence and the model predictions, even in our best-fitting model. Future modelling studies should investigate other factors, such as those listed above, which could bridge the remaining gap between data and the model predictions. Second, clinical immunological studies that can provide more information about the strength and duration of immunity following natural clearance of C. trachomatis would be very valuable. Third, our model predicted a larger reduction in C. trachomatis prevalence if the ratio of screening coverage in infected compared with uninfected individuals remained high. This finding has implications for defining targets for screening performance. After 2011 in the NCSP in England, targets for screening coverage were replaced by indicators for diagnosis rates to maintain high levels of diagnosed infections for a given test volume. 37 The optimal diagnosis rate and its relationship with population prevalence, however, remains unknown. 38 In conclusion, partial immunity against reinfection and changes in differential screening coverage over time might have limited the reduction in C. trachomatis prevalence that would be expected for the level of screening coverage achieved in England. The full range of factors that account for discrepancies between the observed prevalence data and modelpredictions has not been elucidated. Future mathematical modelling studies that aim to investigate the effects of screening interventions on C. trachomatis transmission should incorporate host immunity and changes over time in the targeting of screening.
